Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does REGADENOSON Cause Incorrect product administration duration? 79 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 79 reports of Incorrect product administration duration have been filed in association with REGADENOSON (Regadenoson). This represents 2.6% of all adverse event reports for REGADENOSON.

79
Reports of Incorrect product administration duration with REGADENOSON
2.6%
of all REGADENOSON reports
0
Deaths
12
Hospitalizations

How Dangerous Is Incorrect product administration duration From REGADENOSON?

Of the 79 reports, 12 (15.2%) required hospitalization, and 3 (3.8%) were considered life-threatening.

Is Incorrect product administration duration Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for REGADENOSON. However, 79 reports have been filed with the FAERS database.

What Other Side Effects Does REGADENOSON Cause?

Nausea (311) Dyspnoea (271) Seizure (247) Vomiting (233) Injection site extravasation (226) Hypotension (200) Headache (190) Cardiac arrest (183) Dizziness (160) Blood pressure decreased (143)

What Other Drugs Cause Incorrect product administration duration?

ETONOGESTREL (3,974) POLYETHYLENE GLYCOL 3350 (2,129) NIRMATRELVIR\RITONAVIR (744) DOCOSANOL (634) LANSOPRAZOLE (564) LOPERAMIDE (543) NAPROXEN (499) INSULIN LISPRO (479) DICLOFENAC (362) OMEPRAZOLE (302)

Which REGADENOSON Alternatives Have Lower Incorrect product administration duration Risk?

REGADENOSON vs REGORAFENIB REGADENOSON vs REGORAFENIB\REGORAFENIB REGADENOSON vs RELATLIMAB REGADENOSON vs RELPAX REGADENOSON vs RELUGOLIX

Related Pages

REGADENOSON Full Profile All Incorrect product administration duration Reports All Drugs Causing Incorrect product administration duration REGADENOSON Demographics